<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166061</url>
  </required_header>
  <id_info>
    <org_study_id>TG001</org_study_id>
    <nct_id>NCT01166061</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis</brief_title>
  <official_title>An Escalating, Multiple-dose Study in Grass Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Grass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Grass pollen allergens are universally recognised as a major cause of allergic diseases in
      humans and animals, including asthma, allergic rhinitis, conjunctivitis and dermatitis.
      Worldwide, at least 40% of allergic patients are sensitized to grass pollen allergens and
      between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen.

      ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine,
      currently being developed for the treatment of grass allergy.

      The purpose of the present study is to evaluate the safety and tolerability of multiple
      ascending doses of ToleroMune Grass in subjects allergic to grass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised, double-blind, placebo-controlled study to evaluate
      the safety and tolerability of escalating multiple doses of ToleroMune Grass in subjects with
      a documented history of allergic rhinoconjunctivitis on exposure to grass. The efficacy of
      ToleroMune HDM will also be explored LPSR, EPSR, CPT and levels of grass specific IgE.

      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a
      maximum of 6 weeks before randomisation.

      Period 2 (Treatment Period) will consist of 4 visits (Visits 3A-3D) four weeks apart. The
      first cohort will receive the lowest dose and successive dose groups will increasing doses of
      ToleroMune Grass, provided the first administration of the previous dose was safe and well
      tolerated.

      In Period 3, 2 Post-treatment Challenge visits will take place, the first will be 2 weeks
      after the last administration in the Treatment Period and the second will be 17 weeks after
      the first administration. Follow-up will be conducted 3-10 days after the second PTC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple intradermal injections of ToleroMune Grass in grass allergic subjects with allergic rhinoconjunctivitis</measure>
    <time_frame>Upto 22 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area of Late Phase Skin Response</measure>
    <time_frame>Baseline and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Early Phase Skin Response</measure>
    <time_frame>Baseline and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CPT score</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgG4</measure>
    <time_frame>Baseline and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CPT score</measure>
    <time_frame>Baseline and 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Early Phase Skin Response</measure>
    <time_frame>Baseline and 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgE</measure>
    <time_frame>Baseline and 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Late Phase Skin Response</measure>
    <time_frame>Baseline and 17 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CPT score</measure>
    <time_frame>17 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CPT score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CPT score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgE</measure>
    <time_frame>Baseline and 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive either active or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive either active or placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive either active or placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive either active or placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive either active or placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution resembling active solution but without peptides</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ToleroMune Grass</intervention_name>
    <description>1 x4 administrations 4 weeks apart</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-65 years

          -  Minimum 2 year history of rhinoconjunctivitis on exposure to grass

          -  Positive skin prick test to whole grass allergen

          -  LPSR to whole grass allergen 8-10 hours after intradermal injection of greater than
             35mm diameter response

          -  Positive CPT to whole grass allergen with a score ≥4

        Exclusion Criteria:

          -  Subjects with a history of asthma

          -  Subjects with an FEV1 &lt;80% of predicted

          -  Subjects with a rye grass specific IgE &gt;100 kU/L

          -  Subjects with an acute phase skin response to whole grass allergen with a mean wheal
             diameter &gt; 50 mm

          -  Subjects who score &gt;1 for redness of conjunctiva or who have any watering or itchiness
             in the eye before administration of the CPT

          -  Treatment with beta-blockers, alpha-adrenoreceptor blockers, tranquillisers or
             psychoactive drugs

          -  History of any significant disease or disorder (e.g. cardiovascular, pulmonary,
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,
             malignant, psychiatric, major physical impairment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Hebert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche appliquée en allergie de Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherche Appliqué en Allergie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Rod Hafner, VP R&amp;D</name_title>
    <organization>Circassia Ltd</organization>
  </responsible_party>
  <keyword>Grass Allergy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>ToleroMune Grass</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

